Elafibranor and Choosing Amongst PPAR Agonists in PBC

Author(s):

Nancy Reau, MD,John Vierling, MD, FACP, FAASLD, AGAF

Key Takeaways

Elafibranor, a PPAR-δ agonist, has demonstrated long-term efficacy and safety in treating primary biliary cholangitis (PBC).
Elafibranor and seladelpar both improve liver function in PBC, but differ in receptor selectivity and side effect profiles.
Selecting the right PPAR agonist requires evaluating patient-specific factors, including comorbidities and side effect tolerance.
Monitoring treatment efficacy involves regular liver function tests and assessing symptom improvement for optimal outcomes.

The panel of experts examine the long-term data for the recently FDA-approved PPAR-δ agonist elafibranor in the treatment of primary biliary cholangitis (PBC), comparing its clinical findings with those of seladelpar, and explores how to choose the right peroxisome proliferator-activated receptor (PPAR) agonist and assess treatment effectiveness.

EP: 1.Pathophysiology of PBC

EP: 2.Presentation and Diagnosis of PBC

EP: 3.Differential Diagnosis of PBC

EP: 4.Disease Progression and Extrahepatic Manifestations of PBC

EP: 5.Second-Line Treatments and Management of Symptoms in PBC

EP: 6.Treatment Goals and First-Line Therapy in PBC

EP: 7.Seladelpar for Treatment of PBC

EP: 8.PPAR Agonists for Treatment of PBC

Now Viewing

EP: 9.Elafibranor and Choosing Amongst PPAR Agonists in PBC

EP: 10.Pruritus Control With PPAR Agonists in PBC

Video content above is prompted by the following:

The FDA recently approved another PPAR-δ agonist, elafibranor, for PBC. Could you discuss the long-term data of this agent?
- How do clinical findings for elafibranor compare with those of seladelpar?
- How do you choose the right PPAR agonist for treating PBC, and how do you know if the treatment is working?